ANL 29.68 Increased By ▲ 1.38 (4.88%)
ASC 20.22 Decreased By ▼ -0.03 (-0.15%)
ASL 24.98 Decreased By ▼ -0.12 (-0.48%)
BOP 8.28 Increased By ▲ 0.03 (0.36%)
BYCO 10.31 Increased By ▲ 0.17 (1.68%)
FCCL 22.20 Increased By ▲ 0.28 (1.28%)
FFBL 26.70 Decreased By ▼ -0.05 (-0.19%)
FFL 20.25 Increased By ▲ 0.15 (0.75%)
FNEL 9.03 Increased By ▲ 0.09 (1.01%)
GGGL 27.40 Increased By ▲ 1.15 (4.38%)
GGL 45.63 Increased By ▲ 3.01 (7.06%)
HUMNL 7.28 Increased By ▲ 0.08 (1.11%)
JSCL 21.85 Increased By ▲ 0.45 (2.1%)
KAPCO 39.60 Increased By ▲ 0.41 (1.05%)
KEL 3.91 Increased By ▲ 0.05 (1.3%)
MDTL 3.64 Increased By ▲ 0.10 (2.82%)
MLCF 45.54 Increased By ▲ 1.54 (3.5%)
NETSOL 161.80 Increased By ▲ 3.29 (2.08%)
PACE 7.45 Increased By ▲ 0.25 (3.47%)
PAEL 33.30 Increased By ▲ 0.50 (1.52%)
PIBTL 11.15 Increased By ▲ 0.11 (1%)
POWER 9.20 Increased By ▲ 0.09 (0.99%)
PRL 23.90 Increased By ▲ 0.95 (4.14%)
PTC 12.12 Increased By ▲ 0.29 (2.45%)
SILK 1.79 Increased By ▲ 0.03 (1.7%)
SNGP 50.60 Increased By ▲ 1.10 (2.22%)
TELE 17.04 Increased By ▲ 1.24 (7.85%)
TRG 162.50 Increased By ▲ 4.30 (2.72%)
UNITY 40.80 Increased By ▲ 0.80 (2%)
WTL 3.67 Increased By ▲ 0.15 (4.26%)
BR100 5,189 Increased By ▲ 64.21 (1.25%)
BR30 26,249 Increased By ▲ 598.06 (2.33%)
KSE100 47,758 Increased By ▲ 305.07 (0.64%)
KSE30 19,110 Increased By ▲ 124.84 (0.66%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,529
6724hr
Pakistan Cases
1,043,277
3,58224hr
7.19% positivity
Sindh
387,261
Punjab
358,387
Balochistan
30,627
Islamabad
88,344
KPK
145,306
World

J&J COVID-19 vaccine under EU review over blood clots, AstraZeneca probe grows

  • EMA says no causal link yet of blood clots to either vaccine.
  • Four cases of blood clots in recipients of J&J shots.
  • J&J says working with regulators to assess data on its vaccine.
  • Probe of AstraZeneca vaccine and blood clots already ongoing.
09 Apr 2021

Europe's drug regulator said it is reviewing reports of rare blood clots in four people who received Johnson & Johnson's COVID-19 vaccine and has expanded its probe into AstraZeneca's shot to include reports of a bleeding condition.

Of the four serious cases of clotting and low platelets, three occurred in the United States during the rollout of J&J's vaccine from its Janssen unit, the European Medicines Agency (EMA) said on Friday, adding that one person had died and that one case was reported in a clinical trial.

It was the first news of EMA's probe of the J&J vaccine, while AstraZeneca's coronavirus vaccine has been dogged for weeks over possible links to rare blood clots in the brain and abdomen, which the EMA has confirmed.

US-based J&J said that it was aware of the reports of blood clots possibly related to its COVID-19 vaccine and others, and is working with regulators to assess the data and provide relevant information.

"At present, no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine," the company said in an emailed statement.

The EMA also said that it was not yet clear if there was a link between the two vaccines and the reported conditions, and that its safety committee will decide if regulatory action such as label changes were needed.

Some countries in Europe and Asia have restricted the use of AstraZeneca's vaccine, Vaxzevria, in younger people following an update by EU and UK regulators this week that found a link between the events and the shot. Regulators have said the benefits of the vaccine outweigh the risks.

J&J's single-dose vaccine has been approved for EU use, but a rollout is yet to begin. It is mainly being used in the United States currently.

The EMA also said five cases of capillary leak syndrome in people who received AstraZeneca's vaccine were reported.

The condition, in which blood leaks from the smallest of vessels into muscles and body cavities, is characterised by swelling and a drop in blood pressure. AstraZeneca did not immediately respond to a request for comment.

The J&J and AstraZeneca shots are two of the four approved COVID-19 vaccinations in Europe.